Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.47 |
| ▸ | CNR1 | P21554 | 11/20 | 0.43 |
| ▸ | CNR2 | P34972 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935100 | 0.84 | HTT (0.48) | CNR1CNR2HTT | |
| SCHEMBL4930535 | 0.78 | ALDH1A1 (0.46) | CNR2HTTHDAC3HDAC1HDAC2 | |
| SCHEMBL4925490 | 0.74 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL4933829 | 0.74 | CNR1 (0.41) | CNR1CNR2HTT | |
| SCHEMBL4931381 | 0.73 | CDK2 (0.44) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL4934607 | 0.70 | HTT (0.46) | CNR1CNR2HTTHDAC3HDAC1 | |
| SCHEMBL4934649 | 0.70 | NAMPT (0.48) | CDK2CNR1HTT | |
| SCHEMBL4931772 | 0.69 | MAPK1 (0.50) | HTT | |
| SCHEMBL9629234 | 0.68 | HTT (0.41) | CNR1CNR2HTT | |
| SCHEMBL5171818 | 0.67 | CNR1 (0.44) | CNR1CNR2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | claimed |
| EP-1781647-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-05-09 | — | — | EP | claimed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | claimed |
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | disclosed |
| EP-1781647-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167309-A1 | Pharmaceutical Compounds | CCNO, CDK2, CDK1 | CCNA2 9/4885CDK2 2/4885CCNA1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.